02/05/2016 23:06:06 1-888-992-3836 (toll free) Free Membership Login

Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
02/09/201610:00AMGLOBENymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
HASBROUCK HEIGHTS, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met... More...>>
02/04/201611:15AMGLOBENymox Announces Additional $2.1 Million Equity Financing
HASBROUCK HEIGHTS, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today private placement equity investment of US$2.1 Million. The investment was at $2.00 per share with no warrants. The investment was made by long-term Nymox shareholders. The Company has now... More...>>
12/31/20154:45PMGLOBENymox Files Current Financial Statements
HASBROUCK HEIGHTS, N.J., Dec. 31, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?company=nymox&owner=exclude&action=getcompany... More...>>
12/17/20159:00AMGLOBENymox Provides Update From Shareholders Annual General Meeting December 16
HASBROUCK HEIGHTS, N.J., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented: The Company is moving forward with the activities of preparing... More...>>
10/29/201510:31AMGLOBENymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
HASBROUCK HEIGHTS, N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company's  trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls... More...>>
10/08/201511:00AMGLOBENymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
HASBROUCK HEIGHTS, N.J., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported... More...>>
09/22/20158:12AMPRNUSTechnical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and T...
Technical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and Tesla Motors PR Newswire NEW YORK, September 22, 2015 NEW YORK, September 22, 2015 /PRNewswire/ -- ACI Association has initiated research coverage on the following equities: Bill Barrett Corp (NYSE:... More...>>
05/15/20155:32PMGLOBENymox Reports First Quarter 2015 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards. Nymox reported a net income of $1,576,551, or $0.04 per share for the quarter... More...>>
04/20/201510:00AMGLOBENymox Announces New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years... More...>>
04/01/201510:00AMGLOBENymox Announces Phase 3 BPH Studies
HASBROUCK HEIGHTS, N.J., April 1, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018... More...>>
03/31/20152:30PMGLOBENymox Reports 2014 Financial Results
HASBROUCK HEIGHTS, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,594,093, or $0.13 per share for the... More...>>
03/20/201510:34AMGLOBENymox Announces Private Placements of US$400,000
HASBROUCK HEIGHTS, N.J., March 20, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today recent private placements of 883,058 shares, with total proceeds of US$400,000. An additional 441,529 warrants exercisable at $2.00 were included in the private placements. For more information please... More...>>
01/20/20152:56PMBWUPDATE – UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corp. & I...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014... More...>>
01/19/201510:00PMGLOBENYMOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess ...
NEW ORLEANS, Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2015 to file lead plaintiff applications in a securities class action lawsuit against Nymox Pharmaceutical... More...>>
01/12/20155:33PMGLOBEUPDATE -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporatio...
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (Nasdaq:NYMX) securities between January... More...>>
01/12/20153:09PMGLOBERosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important January 26, 2015 Class Action Deadline -- NYMX...
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action. To join the Nymox class action... More...>>
01/02/201512:53PMPRNUSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX PR Newswire NEW YORK, Jan. 2, 2015 NEW YORK, Jan. 2, 2015 /PRNewswire/ -- Levi & Korsinsky announces that a class... More...>>
12/30/20148:00PMBWSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceu...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) common... More...>>
12/29/20144:31PMBWSHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corp. & Its Board of...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014... More...>>
12/22/20148:18PMGLOBESHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceu...
STEVENSON, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160503 03:06:08